Abstract
Vasculitis poses a great therapeutic challenge to the treating physician. Steroids remain the mainstay of the treatment and biologics are emerging as popular agents. Similar to other immune-mediated diseases, refractory vasculitis seems to be a suitable candidate for bone marrow and mesenchymal stem cell transplantation. Preliminary data show stem cell-based therapies are feasible and effective in severe, treatment-resistant forms of several types of vasculitis. However, due to the fact that patients are rare, clinical data are sparse. Further prospective studies are needed to confirm these preliminary results. In addition, mostly partial remissions are achieved after stem cell transplantation; thus optimization of the therapeutical regimens is necessary through international cooperation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341(17):1284–91.
Barron KS, Shulman ST, Rowley A, et al. Report of the National Institutes of Health workshop on Kawasaki disease. J Rheumatol. 1999;26(1):170–90.
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.
Scott DG, Watts RA. Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis. 2000;59(3):161–3.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(2):315–7.
Figueroa FE, Carrión F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res. 2012;45(3):269–77.
Zhao RC, Liao L, Han Q. Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J Lab Clin Med. 2004;143(5):284–91.
Klinker MW, Wei CH. Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells. 2015;7(3):556–67.
Lee HK, Lim SH, Chung IS, et al. Preclinical efficacy and mechanisms of mesenchymal stem cells in animal models of autoimmune diseases. Immune Netw. 2014;14(2):81–8.
Rad F, Ghorbani M, Mohammadi Roushandeh A, Habibi Roudkenar M. Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles. Mol Biol Rep. 2019;46(1):1533–49.
Jantunen E, Myllykangas-Luosujärvi R. Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives. Bone Marrow Transplant. 2000;25(4):351–6.
Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202.
Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol. 2002;16(3):411–25.
Chartapisak W, Opastiraku S, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch-Schonlein purpura: a systematic review. Arch Dis Child. 2009;94(1):132–7.
Mu K, Zhang J, Gu Y, et al. Cord-derived mesenchymal stem cells therapy for liver cirrhosis in children with refractory Henoch-Schonlein purpura: a case report. Medicine (Baltimore). 2018;97(47):e13287.
Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65(4):508–14.
Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis. 2001;60(7):702–7.
Ashihara E, Shimazaki C, Hirata T, et al. Autoimmune thrombocytopenia following peripheral blood stem cell autografting. Bone Marrow Transplant. 1993;12(3):297–9.
Mccrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation. 2017;135(17):e927–99.
Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014;99(1):74–83.
Noguchi S, Saito J, Kudo T, et al. Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: case series. JA Clin Rep. 2018;4(1):25.
Uchimura R, Ueda T, Fukazawa R, et al. Adipose tissue-derived stem cells suppress coronary arteritis of Kawasaki disease in vivo. Pediatr Int. 2019; https://doi.org/10.1111/ped.14062.
Wedderburn LR, Jeffery R, White H, et al. Autologous stem cell transplantation for paediatric-onset polyarteritis nodosa: changes in autoimmune phenotype in the context of reduced diversity of the T- and B-cell repertoires, and evidence for reversion from the CD45RO(+) to RA(+) phenotype. Rheumatology (Oxford). 2001;40(11):1299–307.
Maffei S, Renzo MD, Bova G, et al. Takayasu’s arteritis: a review of the literature. Intern Emerg Med. 2006;1(2):105–12.
Tanaka F, Kawakami A, Iwanaga N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med. 2006;45(2):313–6.
Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory takayasu arteritis. Int Heart J. 2013;54(2):405–11.
Voltarelli JC, Oliveira MC, Stracieri AB, et al. Haematopoietic stem cell transplantation for refractory Takayasu’s arteritis. Rheumatology (Oxford). 2004;43(10):1308–9.
Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911–20.
Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(9):921–31.
Nanthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of adenosine deaminase type 2 (DADA2): a description of phenotype and genotype in 15 cases. Arthritis Rheumatol. 2016;68(9):2314–2.
Van Montfrans J, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Liao, L., Gu, Y. (2021). Mesenchymal Stem Cell and Hematopoietic Stem Cell Transplantation for Vasculitis. In: Navarro, T.P., Minchillo Lopes, L.L.N., Dardik, A. (eds) Stem Cell Therapy for Vascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-56954-9_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-56954-9_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56953-2
Online ISBN: 978-3-030-56954-9
eBook Packages: MedicineMedicine (R0)